Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
Alps Group Inc (ALPS): Can This Micro-Cap Biotech Climb to $1.50?

Alps Group Inc (ALPS): Can This Micro-Cap Biotech Climb to $1.50?

Key Takeaways

  • The central target of $1.50 is not an analyst consensus; it reflects a technical recovery level discussed in public market commentary, because no credible, attributable analyst price target exists for this micro-cap.
  • At a recent close near $1.18, reaching $1.50 would require a gain of roughly 27%, a substantial move for a stock with this volatility profile.
  • There is no meaningful analyst range to report; coverage is minimal, and aggregated third-party figures for this name appear unreliable or contradictory.
  • The strongest supporting factors are the stock's deeply depressed valuation after a steep drawdown and its small share count, which can amplify moves on any positive catalyst.
  • The biggest risks are ongoing net losses, very low trading liquidity, heavy concentration in an early-stage biotech, and an 83% collapse from its 52-week high.
  • You can find more information about the ticker's Major News, Today's Price Move, Forecast, and Earnings on additional pages, and are welcome to explore them for deeper context.
  • For automated market analysis, explore Trending AI Robots to see AI-driven strategies in action.

Why Analyst Coverage Is Missing

Unlike larger companies, ALPS lacks a set of credible analyst price targets. Sell-side coverage is essentially nonexistent, and any third-party numbers that surface tend to be inconsistent or unreliable. I therefore treat this as a technical recovery discussion rather than a fundamentals-driven forecast.

The $1.50 level comes from market commentary focused on the stock's prior consolidation zones after its long decline from a 52-week high near $8.60. It is a publicly discussed technical objective, not a broker-issued target.

Current Position and the Path to $1.50

Shares recently closed near $1.18, placing the market capitalization around $37–39 million within a 52-week range of roughly $1.01 to $8.60. A move to $1.50 would represent an approximate 27% advance—meaningful for any micro-cap, especially one that has already lost most of its value.

Fundamentals remain limited, with trailing-twelve-month revenue in the low single-digit millions and ongoing net losses. Any advance would likely stem from sentiment shifts, financing news, partnership announcements, or pipeline progress rather than improved current earnings. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Factors That Could Support a Recovery

  • Depressed valuation and limited float: A market cap near $37–39 million combined with a small share count means even modest buying can drive sharp moves.
  • Clinical or business milestones: Credible progress in stem-cell or advanced-therapy programs could quickly improve sentiment.
  • New capital or partnerships: Fresh financing or collaborations might ease liquidity concerns and serve as catalysts.
  • Sector tailwinds: A broader risk-on environment for speculative biotech and small-cap names would help.

Risks That Could Block the Target

  • Continued losses: Ongoing net losses and minimal revenue keep the company reliant on external funding.
  • Low liquidity: Very thin average daily volume can exaggerate price swings and complicate exits.
  • Dilution potential: Negative cash flow often leads micro-caps to issue new shares, which can weigh on the price.
  • Technical resistance: After an 83% drop from the high, overhead supply and weak confidence may limit rebounds.
  • Concentration risk: An early-stage biotech focused on one area carries binary outcomes tied to research and regulatory results.

Technical Structure to Watch

The long-term chart remains damaged, with shares near the bottom of the 52-week range. The $1.50 area stands out as a round-number psychological level that previously served as a consolidation zone. Support to watch lies at the $1.01 low, while any move above $1.50 would encounter layers of prior trading activity and resistance as the stock tries to repair its downtrend.

What to Monitor Going Forward

Because the target is technical rather than analyst-derived, there is no formal research timeline. I keep an eye on quarterly results and cash position, updates to the research pipeline, any financing or partnership news, and changes in share count that might indicate dilution. Broader conditions in small-cap biotech also matter, along with price action around the $1.01 support and $1.50 resistance levels.

Using AI Tools in My Research

One tool I often turn to for names like this is AI Daily Buy/Sell Signals from Tickeron. These signals apply artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold recommendations based on technical behavior and shifting market conditions. For a low-liquidity micro-cap where traditional coverage is scarce, the system helps surface trend changes and emerging opportunities more efficiently than manual review alone. Traders looking to streamline daily analysis can explore these signals as a complement to their own work.

Final Assessment

The $1.50 objective for ALPS is a technical recovery level drawn from public discussion, not a published analyst consensus. Reaching it would require a substantial gain of roughly 27% from recent prices near $1.18. Supporting the case are the stock’s tiny market capitalization, low float, and deeply depressed valuation, which could magnify any positive catalyst. Working against it are persistent losses, minimal revenue, illiquidity, dilution risk, and a severely damaged long-term chart. Whether ALPS can reach $1.50 will depend heavily on business milestones, financing, and sentiment in speculative biotech, and investors should weigh those factors carefully rather than treat the figure as a forecast or a certainty.

Promo Section

In my own workflow I regularly use Tickeron’s AI tools to cross-check ideas and monitor low-coverage names. The platform’s AI Daily Buy/Sell Signals and related engines help me stay on top of technical shifts without spending hours on manual screening. I find them especially useful when traditional analyst data is thin or unavailable.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ALPS

ALPS in -26.88% downward trend, sliding for three consecutive days on November 12, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ALPS declined for three days, in 62 of 79 cases, the price declined further within the following month. The odds of a continued downward trend are 78%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALPS as a result. In 22 of 69 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 32%.

The Moving Average Convergence Divergence Histogram (MACD) for ALPS turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 14 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 27%.

The 10-day moving average for ALPS crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 4 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 33%.

The Aroon Indicator for ALPS entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +5.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALPS advanced for three days, in 35 of 71 cases, the price rose further within the following month. The odds of a continued upward trend are 49%.

ALPS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (3.592). P/E Ratio (0.000) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (13.699) is also within normal values, averaging (442.120).

The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. ALPS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALPS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -11%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was -24%. SLS experienced the highest price growth at 129%, while CUE experienced the biggest fall at -85%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was 10% and the average quarterly volume growth was -15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
No. 1, Jalan 1/68th Floor, Off Jalan Tun Razak
Phone
+60 321631113
Employees
89
Web
https://www.alps-holdings.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.